Ranitidine

is prescribed to treat:

• Heartburn and stomach ulcers • Various related conditions in the gastrointestinal category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Ranitidine (formerly Zantac) is an H2 receptor antagonist that was used for gastroesophageal reflux disease, peptic ulcer disease, and heartburn. It was withdrawn from the United States market in April 2020 and is no longer available. If you were taking it, this page explains why it was removed and what replaced it.

Why Ranitidine Was Withdrawn

In 2019, testing detected N-nitrosodimethylamine — NDMA — in ranitidine products. NDMA is classified as a probable human carcinogen, and permissible daily intake limits are very low.

What made ranitidine different from other contamination recalls was the source of the problem. Rather than a manufacturing defect confined to particular batches, evidence indicated that NDMA could form from the ranitidine molecule itself over time, with levels rising during storage and at higher temperatures. A contaminated batch can be recalled; a molecule that generates a carcinogen as it ages cannot be manufactured around.

The FDA therefore requested removal of all ranitidine products, prescription and over-the-counter, in April 2020. Regulators in other countries took similar action. The FDA ranitidine withdrawal announcement sets out the reasoning in full.

Products now sold as Zantac in the United States contain famotidine, a different H2 blocker, not ranitidine. The brand name was retained while the active ingredient was replaced — a source of genuine confusion for patients who believe they are still taking the drug they were prescribed years ago.

What Replaced It

Famotidine is the direct substitute and is now the standard H2 blocker. It works by the same mechanism, has not shown the NDMA problem, and is available both over the counter and on prescription. Patients previously taking ranitidine were generally switched to it directly.

Where acid suppression needs to be stronger, a proton pump inhibitor such as omeprazole or pantoprazole is used. PPIs suppress acid more completely than H2 blockers because they act on the proton pump itself, the final common step of acid secretion, rather than on one of several signals that stimulate it.

The two classes have different profiles rather than a simple hierarchy. H2 blockers act faster — within about an hour — and suit intermittent or as-needed use. PPIs take days to reach full effect and suit sustained suppression, but require correct timing before a meal and carry the long-term considerations that come with prolonged acid suppression. The long-term PPI article covers those, and our gastrointestinal team manages reflux that is not responding.

How H2 Blockers Work

H2 receptor antagonists competitively block histamine H2 receptors on gastric parietal cells. Histamine released from enterochromaffin-like cells is one of three signals — alongside gastrin and acetylcholine — that stimulate the proton pump to secrete acid. Blocking the histamine pathway reduces acid output substantially but not completely, since the other two pathways remain intact.

This partial blockade is why H2 blockers are less potent than PPIs and why tolerance develops to them: with continued use over days to weeks, the acid-suppressing effect diminishes, a phenomenon that does not occur with PPIs. For intermittent symptom relief this hardly matters; for continuous treatment it does, and it is one reason PPIs displaced H2 blockers for erosive disease.

Famotidine is renally cleared and requires dose reduction in kidney impairment — a frequently missed adjustment in older patients, where accumulation causes confusion.

If You Took Ranitidine

The practical question most people have is whether past use is harmful. The available evidence has not demonstrated an increased cancer risk in people who took ranitidine, and the withdrawal was a precautionary action based on the presence of a probable carcinogen rather than on observed harm in patients.

No specific screening or testing is recommended for people who previously took it. Any remaining supplies should be disposed of rather than used, since NDMA levels rise with storage age.

What is worth reviewing is whether ongoing acid suppression is still needed at all. Many patients who were on long-term ranitidine were switched to famotidine or a PPI and have continued indefinitely without anyone revisiting the indication. Uncomplicated reflux controlled for a sustained period is often a candidate for step-down or discontinuation, whereas Barrett's esophagus, severe erosive esophagitis, or ongoing ulcer risk generally justify continuing. The MedlinePlus famotidine entry covers the current standard agent.

Alarm Features That Change the Approach

Regardless of which acid-suppressing drug is used, certain features mean the answer is investigation rather than more medication. Difficulty or pain on swallowing, unintended weight loss, persistent vomiting, gastrointestinal bleeding, or iron deficiency anemia all warrant endoscopy.

This matters because acid suppression can relieve the symptoms of gastric malignancy while the underlying disease progresses — the reason empiric treatment without reassessment is inappropriate in anyone with these features, or in an older patient with new-onset symptoms.

Lifestyle measures remain worth pursuing alongside any medication, since they address mechanism rather than only acid. Weight loss has the strongest evidence in overweight patients, and elevating the head of the bed and avoiding food within three hours of lying down help nocturnal symptoms specifically.

When to Contact Your Doctor

Seek prompt evaluation for difficulty or pain on swallowing, unintended weight loss, black or tarry stools, vomiting blood, or persistent vomiting — none of these should be managed by increasing acid suppression.

If you are still taking a ranitidine product from before the withdrawal, stop and dispose of it. If you were switched to famotidine or a PPI and have been taking it for years, ask whether it is still needed and at what dose. Report reflux symptoms that persist despite consistent treatment, since that usually indicates a different diagnosis rather than insufficient acid suppression.

To review what replaced your ranitidine, whether you still need acid suppression, or reflux that is not responding, contact us or schedule a visit.